The Case CCC Imaging Research Core Facility provides researchers with state-of-the art facilities and the services for in vivo imaging. The facility provides cancer researchers its extensive imaging research infrastructure and expertise of -26 imaging faculty in Radiology, Chemistry, Physics, and Biomedical Engineering to enhance and expand ongoing research efforts. The advent of dedicated small animal imaging systems allows the integration of in vivo physiologic measurements with microscopic measurements of structural and cellular activities. The collaborative, multidisciplinary approach provides a wealth of new information in elucidating the complex relationship between structure, genetics, replication, and function in genetically manipulated animal models of disease that have been used widely in cancer research with grounding in cellular/molecular-level understanding. The Imaging Research Core Facility is the centerpiece of the Case Center for Imaging Research, which encompasses all aspects of the much broader imaging research program at Case/UH. This includes molecular imaging, small animal imaging, and clinical imaging thrusts. The Core provides services to Case CCC members from 7 of 8 research programs, with members from the Imaging Program and Cancer Cell Signaling utilizing the Core's services the most. The Core has been actively involved in studies of the glioma microenvironment where novel cryo-imaging techniques demonstrated migration and dispersal pathways in vivid three-dimensional detail. In addition, fluorescence imaging systems in the Core were used to discover that while activation of EphA2 with its ligand ephrin-AI inhibits chemotactic migration of glioma and prostate cancer cells, EphA2 over-expression promotes migration in a ligand-independent manner.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182|
|Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266|
|Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:|
|Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151|
|Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231|
|Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903|
|Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376|
|Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237|
|Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601|
|Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643|
Showing the most recent 10 out of 1227 publications